Nancy X. Deng
Partner
Patent Agent
Article
6
Femtech, defined as technology and innovation focused on women’s health, has rapidly evolved from a niche sector into a cornerstone of the modern healthcare economy. The industry addresses critical gaps in care for menstrual health, fertility, pregnancy, menopause, and chronic conditions disproportionately affecting women.
According to the McKinsey Health Institute[1], closing the women’s health gap and scaling women’s health technologies could unlock roughly USD 1 trillion in additional global GDP annually by 2040 and add about USD 27 billion to Canada’s GDP[2], underscoring the significant economic gains at stake.
This rapidly expanding market makes strategic intellectual property protection essential for innovators in the Femtech space. Effective IP strategies for Femtech begin by securing the core technology with patents and the consumer trust with trademarks, creating defensible moats that help founders safeguard breakthrough technologies, attract investment, and ensure sustainable commercial success in the face of unique subject matter eligibility challenges characteristic of women’s health technologies.
Patents safeguard technological innovations by granting time-limited exclusivity over new, useful, and non-obvious inventions. For Femtech ventures, this can encompass device architectures, sensor assemblies, signal processing pipelines, diagnostic methods, therapeutic delivery mechanisms, formulations, and computer-implemented inventions that produce a concrete technical effect.
Canada provides a limited grace period for an applicant’s own disclosures made within the year preceding the Canadian filing date, but public disclosure before filing can forfeit rights in many foreign jurisdictions. As a result, founders should prioritize pre-filing confidentiality and coordinate publication, marketing, and clinical study timelines with patent counsel.
For medical and health technologies, claim‑drafting nuances matter; and the law is evolving. In Canada, the Supreme Court of Canada is currently considering the patent eligibility issue of methods of medical treatment[3], until its decision issues, such methods remain generally unpatentable.
However, devices for medical treatment, diagnostic methods, and “uses” of a device or drug for medical treatment are patent‑eligible. Careful claim strategy—focusing on patent-eligible subject matter such as devices, systems, and certain “use” claims, and avoiding active medical or surgical steps or elements that require a clinician’s skill and judgment—can help mitigate risk.
By contrast, the United States permits methods of medical treatment, though diagnostic method claims can face eligibility scrutiny. For global portfolios, it is essential to coordinate filing and claim strategies early so claims can be tailored to local eligibility doctrines and to optimize protection in each jurisdiction.
For computer‑implemented inventions—particularly AI/ML‑enabled analytics common in Femtech— eligibility challenges can arise as the Patent Office applies a “physicality” requirement to prevent claims from merely reciting an abstract algorithm or data analysis. One can satisfy this requirement by anchoring the invention to specific physical hardware components (such as integrated sensors) and/or demonstrating improvements in computer functioning, and by framing the invention as a tangible, practical application with real‑world technical and commercial value.
While datasets themselves are not patentable, inventions that transform, process, or use data to produce a technical effect can be. Early engagement with experienced patent counsel helps position claims to satisfy eligibility and support enforceability.
Procedurally, examination must be requested within prescribed time limits, and acceleration mechanisms may be available, including programs that leverage favorable outcomes in partner jurisdictions. A well-managed prosecution strategy can reduce pendency, preserve broad claim scope, and align issuance with commercialization milestones.
In a field as intimate and trust-dependent as Femtech, branding is not just about visibility—it’s about credibility. Consumers want to feel secure using apps, devices, and platforms that handle sensitive health data. Trademarks, which protect names, logos, slogans, and other brand identifiers, serve as a guarantee of origin and quality.
A trademark registered with the Canadian Intellectual Property Office (CIPO) grants exclusive rights to use the mark across Canada in connection with defined goods or services. This legal recognition helps Femtech founders prevent competitors from adopting confusingly similar branding, thereby reducing the risk of reputational damage or customer confusion.
For example, Elvie, though based in the UK, has filed for protection in Canada due to its pelvic health devices being distributed here. Canadian firms must be just as proactive in protecting their marks abroad.
With more Femtech startups entering the Canadian and global markets, a well-defined and protected brand becomes a key differentiator.
Take Ova Health, a London-based startup which is developing smart sensors to deliver real-time hormonal insights for menopause health. It is developing a brand strategy to position itself so that it can safely promote its brand within Canada and abroad. Trademark protection ensures that its brand identity remains exclusive and enforceable.
Early-stage Femtech ventures often rely on venture capital and strategic partnerships. A registered trademark adds value to a company’s portfolio by demonstrating that its brand assets are protected and enforceable.
Trademark registration provides access to powerful enforcement mechanisms. For Canadian Femtech brands with e-commerce operations—especially those selling products via platforms like Amazon or advertising on Instagram—a registered mark facilitates takedown requests and digital rights enforcement.
Moreover, if a competitor in Canada were to use a similar name, logo, or slogan, the owner of a registered trademark could initiate action under the Trademarks Act, seeking remedies such as injunctions, damages, or an accounting of profits.
Register early: Canadian law allows for the filing of trademarks based on “proposed use.” Don’t wait for your product to hit the market—secure your mark as part of your launch strategy.
Do the due diligence: Conduct comprehensive clearance searches, ideally with professional legal assistance, to avoid conflicts and potential litigation.
Plan for global expansion: Consider future markets. Through the Madrid Protocol, Canadian businesses can apply for international trademark protection using a single, streamlined process.
Canada’s Femtech sector is gaining momentum, driven by startups that are innovating with purpose and social impact. A holistic IP strategy—anchored by both patents and trademarks—is a practical cornerstone of that effort.
By filing patents early, drafting claims that survive eligibility scrutiny, and integrating prosecution with commercialization, founders can secure durable advantages that compound over time, yielding defensible differentiation, stronger investor readiness, and more productive partnerships.
In parallel, trademark protection is essential to transform inventive ideas into lasting brands: it builds trust with users, attracts investment, and helps fend off infringement as companies scale. Together, patents that protect core technology and registered trademarks that safeguard brand identity provide a clear path to global growth for any Canadian Femtech entrepreneur aiming to lead in this transformative space.
For more information or to answer any questions, please contact one of the authors or a member of our Intellectual Property Group.
[1] https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies
[2] https://femtech.ca/canadas-37-billion-opportunity-why-closing-the-womens-health-gap-is-our-smartest-investment/
[3] On October 9, 2025, the Supreme Court heard oral arguments in Pharmascience Inc v Janssen Inc (Supreme Court File No 41209) and reserved its decision to a later date.
NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.